Moderate-to-severe atopic dermatitis (AD) often requires ongoing biologic therapy, yet patients who discontinue dupilumab may have limited alternative options. To address this need, a study evaluated the efficacy and safety of lebrikizumab, which has a distinct mechanism of action, in 86 adults and adolescents with prior dupilumab exposure. The study found that the primary reasons for discontinuing dupilumab were inadequate response (55.8%), adverse events or intolerance (16.3%), and other reasons (27.9%).
With lebrikizumab, response rates at weeks 16 and 24 were 57.4% and 60.0% for Eczema Area and Severity Index (EASI) 75, 53.2% and 61.5% for ≥4-point improvement in pruritus scores, and 83.0% and 83.0% for quality-of-life improvement. Most adverse events were mild to moderate, with serious events reported in 2/86 (2.3%) and discontinuations in 5/86 (5.8%) patients, and no…
